Please provide your email address to receive an email when new articles are posted on . A protein known as granzyme K was recently shown to be a driver of inflammation by activating the complement ...

A case report describes a 14-year-old boy whose common cold virus triggered atypical hemolytic uremic syndrome with severe skin necrosis that required surgical debridement after drug therapy failed.

Repurposing complement inhibitors to see whether they are effective against neurodegenerative diseases is already in development. (Artur Plawgo/iStock/Getty Images Plus) With Alzheimer’s disease ...

In a recent study posted to the bioRxiv* pre-print server, researchers investigated the complement component 1q (C1q) binding and subsequent complement activation by neutralizing antibodies (nAbs) ...

AJMC ®: How has treatment of complement-driven diseases changed since 2007, when the first complement inhibitor, eculizumab, was approved? SMITH: The development of eculizumab followed our ...

Clinicogenomic landscape and outcomes of metastatic colorectal cancer patients with pathogenic GNAS variants. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract does ...